Conformational Dynamics in the Cell Membrane Interactions of Bispecific Targeted Degrader Therapeutics. [PDF]
J Med ChemInganäs E +7 more
europepmc +1 more source
Targeted protein degradation: species, diseases and efficient utilization. [PDF]
J Transl MedYue T, He J, Hou J.
europepmc +1 more source
Chimeric degraders in neurodegenerative diseases: Challenges and future directions. [PDF]
J Transl Int MedZheng H, Cui K, Mao J, Wan Y, Zheng J.
europepmc +1 more source
Evolution of proteolysis-targeting chimeras (PROTAC) technology to overcome challenges of antimicrobial resistance. [PDF]
NPJ Antimicrob ResistSarwan DN +3 more
europepmc +1 more source
Therapeutic horizons in the development of PROTAC-based EZH2 inhibitors: recent achievements, comparative analysis, and future perspectives. [PDF]
RSC AdvS Abulkhair H.
europepmc +1 more source
Insights into the Design of MYC-Targeting Proteolysis Targeting Chimeras (PROTACs). [PDF]
MoleculesAlfayomy AM +6 more
europepmc +1 more source
Post-Covid Alzheimer and Its Remediation via PROTACs Therapy: A Comprehensive Review. [PDF]
Health Sci RepBhowmick T +5 more
europepmc +1 more source
Dual Aptamers-Based SETDB1 PROTACs as Effective Anti-Tumor Strategies for Breast Cancer. [PDF]
Adv Sci (Weinh)Guo Y +6 more
europepmc +1 more source
Next-Generation Proteolysis-Targeting Chimeras in Precision Oncology: Multifunctional Designs, Emerging Modalities, and Translational Prospects in Targeted Protein Degradation. [PDF]
Drug Dev ResNafie MS +6 more
europepmc +1 more source
Emerging Strategies to Inhibit the G1/S Transition for Cancer Therapy. [PDF]
Cancer ResRubin SM, Sage J, Skotheim JM.
europepmc +1 more source